Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of otilimab vs placebo and sarilumab in rheumatoid arthritis (Japan)
jRCT2080224947Phase 3Completed
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (6 arms). Primary endpoint: ACR20 response at Week 12. Started Nov 2019; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080224947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224947.